Compounds which inhibit leukocyte adhesion mediated by VLA-4

Details Compounds which inhibit leukocyte adhesion mediated by VLA-4 Compounds which inhibit leukocyte adhesion mediated by VLA-4

2007-01-23

2007-01-23

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C548S535000, C562S553000

Reexamination Certificate

active

10266889

ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4069318 (1978-01-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4071621 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4097591 (1978-06-01), Okamoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4260601 (1981-04-01), Reichelt et al.
patent: 4804676 (1989-02-01), Inaoka et al.
patent: 4910190 (1990-03-01), Bergeson et al.
patent: 4977168 (1990-12-01), Bernat et al.
patent: 4981873 (1991-01-01), Witte et al.
patent: 4992421 (1991-02-01), De et al.
patent: 5338755 (1994-08-01), Wagnon et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5397801 (1995-03-01), Wagnon et al.
patent: 5481005 (1996-01-01), Wagnon et al.
patent: 5578633 (1996-11-01), Wagnon et al.
patent: 5650428 (1997-07-01), Ohmori et al.
patent: 6221888 (2001-04-01), Durette et al.
patent: 6147073 (1975-04-01), None
patent: 23 57 334 (1974-06-01), None
patent: 26 55 636 (1977-06-01), None
patent: 0 526 348 (1993-02-01), None
patent: 9711143.9 (1997-05-01), None
patent: 9714314.3 (1997-07-01), None
patent: 9714316.8 (1997-07-01), None
patent: 9714335.8 (1997-07-01), None
patent: 9722674.0 (1997-10-01), None
patent: 9800680.2 (1998-01-01), None
patent: 9800684.4 (1998-01-01), None
patent: 9800686.9 (1998-01-01), None
patent: 08073422 (1996-03-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 94/07815 (1994-04-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/20725 (1996-07-01), None
patent: WO 96/20949 (1996-07-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 97/48726 (1997-12-01), None
patent: WO 98/04247 (1998-02-01), None
patent: WO 98/42656 (1998-10-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 98/53818 (1998-12-01), None
patent: WO 98/54207 (1998-12-01), None
patent: WO 98/58902 (1998-12-01), None
patent: 99/06432 (1999-02-01), None
patent: 99/06436 (1999-02-01), None
patent: 99/10312 (1999-03-01), None
patent: 99/10313 (1999-03-01), None
patent: 99/67230 (1999-12-01), None
Simanis, Viesturs (International Journal of Peptide & Protein Research 19(1), 67-70, 1982).
Abbas, Y. A. (Egyptian Journal of Pharmaceutical Sciences 36(1-6), 187-95, 1995).
V. Simanis, et al.,Int. J. Pept. Protein Res. (1982), 19(1), 67-70.
D. Leibfritz, et al.,Tetrahedron(1982), 38(14), 2165-81.
A. M. El-Naggar, et al.,Acta. Pharm. Jugosl. (1985), 35(1), 15-22.
Chemical Abstract No. 126040, vol. 74, No. 23 (Jun. 7, 1971).
Chemical Abstract No. 176262, vol. 99, No. 21 (Nov. 21, 1983).
Chemical Abstract No. 210288, vol. 106, No. 25 (Jun. 22, 1987).
Chemical Abstract No. 167952, vol. 108, No. 19 (May 9, 1988).
Chemical Abstract No. 34164, vol. 125, No. 3 (Jul. 15, 1996).
Engleman, V.W., et al. “Cell Adhesion Integrins as Pharmaceutical Targets.”Ann. Reports in Med. Chem. 31: 191-200 (1996).
Gamo, K. “Optical resolution of racemic amine derivatives.”Chem. Abs. 117: 211689 (1992).
Hauptmann, J., et al. “Degradation of a Benzamidine-Type Synthetic Inhibitor of Coagulation Enzymes in Plasma of Various Species.”Thrombosis Research. 61: 279-284 (1991).
Voigt, B., et al. “Synthese von Nα-(Arylsolfonyl-L-prolyl)-und Nα-Benzyloxycarbonyl-L-prolyl)-D,L-4-amidinophenyl-alaninamiden als Thrombininhibitoren.”Pharmazie. 41: 233-235 (1986).

Affiliated with

Also associated with

Rating

Compounds which inhibit leukocyte adhesion mediated by VLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds which inhibit leukocyte adhesion mediated by VLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds which inhibit leukocyte adhesion mediated by VLA-4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3823710